Abstract:Xinwei Zhou, 1, &ast Ke Lin, 2, &ast Liangmin Fu, 1, &ast Fei Liu, 3, &ast Hansen Lin, 1 Yuhang Chen, 1 Bowen Zhuang, 2 Hui Liang, 4 Qiong Deng, 4 Zhu Wang, 4 Wei Chen, 1 Junhang Luo, 1, 5 Jiazheng Cao, 6 Pengju Li 1 1 Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; 2 Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; 3 Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 4 Department of Urology, Affiliated Longhua People's Hospital, Southern Medical University, Shenzhen, People's Republic of China; 5 Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China; 6 Department of Urology, Jiangmen Central Hospital, Jiangmen, People's Republic of China &astThese authors contributed equally to this work Correspondence: Pengju Li, Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan Road II, Guangzhou, 510080, People's Republic of China, Tel +86-20-87618227, Email Jiazheng Cao, Department of Urology, Jiangmen Central Hospital, Haibang Street 23, Jiangmen, 529030, People's Republic of China, Tel +86-750-3165500, Email Background: Triggering receptors expressed by myeloid cells-1 (TREM1) is a receptor belonging to the immunoglobulin superfamily and plays an important role in pro-inflammation in acute and chronic inflammatory disorders. However, the understanding of the immunomodulatory roles of TREM1 in the tumor microenvironment remains incomplete. Methods: The expression patterns of TREM1 mRNA in tumors and adjacent normal tissues were compared by analyzing data obtained from the Genotype-Tissue Expression and The Cancer Genome Atlas datasets. Survival analysis was performed to determine the prognostic value of TREM1. Functional enrichment analysis was applied to decipher the discrepancy in biological processes between high- and low-TREM1 groups across various cancers. The correlation between TREM1 and immune cell infiltration determined by using multiple algorithms was evaluated with the Pearson method. Four independent immunotherapy cohorts were adopted to validate the role of TREM1 as a biomarker. Results: TREM1 was elevated in most cancers as verified with clinical samples. Overexpression of TREM1 was linked with undesirable prognosis in patients. Further analysis revealed that TREM1 was positively correlated with immune response, pro-tumor pathways, and myeloid cell infiltration, while being negatively correlated with CD8 + T cell (including infiltration level and biological processes). Concordantly, tumors with high TREM1 levels were more resistant to immunotherapy. Through connective map analysis, therapeutically potential compounds like tozasertib and TPCA-1 were identified, which can be used synergistically with immunotherapy to improve the poor prognosis of patients with high TREM1 levels. Conclusion: Through a systematic and comprehensive pan-cancer analysis, we demonstrated that overexpression of TREM1 in tumors correlated closely with unfavorable outcome, infiltration of immune-suppressive cells, and immune regulation, which highlights its potential use as a tumor prognostic biomarker and a novel target for immunotherapy. Keywords: triggering receptors expressed by myeloid cells-1, pan-cancer, prognostic biomarker, tumor microenvironment, clear cell renal cell carcinoma, immunotherapy The tumor microenvironment (TME) is a collective term that includes tumor cells and the non-neoplastic components with which they interact. Changes in the TME often affect multiple biological functions in tumors. 1 Although "inflammatory" type tumors characterized by high immune cell infiltration are considered to have a better prognosis and a better response to immunotherapy, chronic inflammation is inextricably linked with tumor development and immune escape. 2 Studies have confirmed that the presence of long-term chronic infection is highly related to the risk of tumors at the same location, and many cancers occur at the sites of chronic inflammation. 3 Cancer-related inflammation is even considered the seventh hallmark of cancer. 4 Ther -Abstract Truncated-

Abstract 6530: TREM1 inhibition: A novel approach to suppress tumor growth and enhance immune checkpoint therapy

TREM1 activation of myeloid cells promotes antitumor immunity

TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy

Triggering Receptor Expressed on Myeloid Cells-2 (TREM-2) Elicited by Lung Cancer Cells to Facilitate Tumor Immune Evasion.

Abstract 3718: Deciphering the role of TREM2+ tumor-associated macrophages as mediators of immunoresistance in micro-satellite stable colorectal metastases

Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes

The rationale of reprogramming TREM2+ macrophages for overcoming the resistance to immune checkpoint inhibitors in pancreatic adenocarcinoma.

Abstract 5209: Generation of humanized TREM2 mice for preclinical evaluation of therapeutics targeting tumor-associated macrophages

Abstract 3555: TREM2 is Upregulated and Plays Oncogenic Role in Gastric Cancer

Abstract 3923: Targeting immunosuppressive TREM2+tumor associated macrophages in prostate cancer

Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression

TREM1: Activation, signaling, cancer and therapy

Abstract A057: Therapeutic modality, antitumor efficacy and immune safety for targeting innate immune checkpoint TREX1 as cancer immunotherapy

Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer

Triggering Receptor Expression on Myeloid Cells-1 (TREM1) Promoter Hypomethylation and Its Overexpression Associated With Poor Survival of Cancer Patients: A Pan-Cancer Analysis

Abstract 4987: TREM2 is a radiation-induced target for immunomodulation of tumor-associated macrophages in the prostate cancer tumor microenvironment

TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma

TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti–PD-1 tumor immunotherapy

Targeting the TREM1-positive myeloid microenvironment in glioblastoma

Platinum‐Based TREM2 Inhibitor Suppresses Tumors by Remodeling the Immunosuppressive Microenvironment

TREM2+ Macrophages Suppress CD8+ T-cell Infiltration after Transarterial Chemoembolisation in Hepatocellular Carcinoma.